Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tadalafil Tablets USP, 2.5 mg, 5 mg, 10-mg and 20 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg, of Eli Lilly and Company (Lilly). All strengths of Tadalafil Tablets are indicated for the treatment of erectile dysfunction (ED).
Tadalafil Tablet 5mg strength is additionally indicated for treatment of signs and symptoms of benign prostatic hyperplasia (BPH). Alembic had previously received tentative approval for this ANDA. Tadalafil Tablets have an estimated market size of $1.8 billion for twelve months ending December 2018 according to IQVIA.
Alembic now has a total of 89 ANDA approvals (77 final approvals and 12 tentative approvals) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
